Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer

BJU International

Volumn 110, Issue 11, 2012, Pages 1729-1735

  Nakabayashi, Mari ^a   Werner, Lilian ^a   Courtney, Kevin D ^a,e   Buckle, Geoffrey ^a   Oh, William K ^c   Bubley, Glen J ^b   Hayes, Julia H ^a   Weckstein, Douglas ^d   Elfiky, Aymen ^a   Sims, Danny M ^d   Kantoff, Philip W ^a   Taplin, Mary Ellen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d New Hampshire Oncology Hematology   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bicalutamide; castration resistant prostate cancer; everolimus; mTOR; RAD001

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; EVEROLIMUS; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANAL COMPLAINT; ANDROGEN DEPRIVATION THERAPY; ANUS DISEASE; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LIVER FUNCTION TEST; LUNG INFILTRATE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TREATMENT DURATION;

EID: 84870901238     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11456.x     Document Type: Article

References (52)

1. Taplin ME,. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007; 4: 236-44
2. Taplin ME, Rajeshkumar B, Halabi S, et al,. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-8
3. Taplin ME, Bubley GJ, Ko YJ, et al,. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59: 2511-5
4. Taplin ME, Bubley GJ, Shuster TD, et al,. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393-8
5. Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME,. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer 2011; 9: 95-103
6. Kucuk O, Fisher E, Moinpour CM, et al,. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58: 53-8
7. Joyce R, Fenton MA, Rode P, et al,. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159: 149-53
8. Scher HI, Liebertz C, Kelly WK, et al,. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928-38
9. Montgomery RB, Mostaghel EA, Vessella R, et al,. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54
10. Stanbrough M, Bubley GJ, Ross K, et al,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-25
11. Cai C, Balk SP,. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer 2011; 18: R175-82
12. Cai C, Chen S, Ng P, et al,. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71: 6503-13
13. Luo J, Manning BD, Cantley LC,. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-62
14. Schayowitz A, Sabnis G, Goloubeva O, Njar VC, Brodie AM,. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. Br J Cancer 2010; 103: 1001-7
15. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM,. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008; 27: 7106-17
16. Xu Y, Chen SY, Ross KN, Balk SP,. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res 2006; 66: 7783-92
17. Cinar B, De Benedetti A, Freeman MR,. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin. Cancer Res 2005; 65: 2547-53
18. Carver BS, Chapinski C, Wongvipat J, et al,. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86
19. Manin M, Baron S, Goossens K, et al,. Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem J 2002; 366: 729-36
20. Steck PA, Pershouse MA, Jasser SA, et al,. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-62
21. Li J, Yen C, Liaw D, Podsypanina K, et al,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7
22. Cantley LC, Neel BG,. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-5
23. Taylor BS, Schultz N, Hieronymus H, et al,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22
24. Deocampo ND, Huang H, Tindall DJ,. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-53
25. Bjornsti MA, Houghton PJ,. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48
26. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J,. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16: 1472-87
27. Lane HA, Wood JM, McSheehy PM, et al,. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009; 15: 1612-22
28. Houghton PJ,. Everolimus. Clin Cancer Res 2010; 16: 1368-72
29. Motzer RJ, Escudier B, Oudard S, et al,. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2011; 116: 4256-65
30. Motzer RJ, Escudier B, Oudard S, et al,. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56
31. Majumder PK, Febbo PG, Bikoff R, et al,. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601
32. Podsypanina K, Lee RT, Politis C, et al,. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001; 98: 10320-5
33. Neshat MS, Mellinghoff IK, Tran C, et al,. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-9
34. Zhang W, Zhu J, Efferson CL, et al,. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-72
35. Therasse P, Arbuck SG, Eisenhauer EA, et al,. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16
36. Scher HI, Halabi S, Tannock I, et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
37. Benjamin D, Colombi M, Moroni C, Hall MN,. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-80
38. Guertin DA, Sabatini DM,. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22
39. Shaw RJ, Cantley LC,. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30
40. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM,. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101
41. Sarbassov DD, Ali SM, Kim DH, et al,. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-302
42. O'Reilly KE, Rojo F, She QB, et al,. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8
43. Tabernero J, Rojo F, Calvo E, et al,. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-10
44. Breuleux M, Klopfenstein M, Stephan C, et al,. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009; 8: 742-53
45. Carracedo A, Ma L, Teruya-Feldstein J, et al,. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-74
46. Mazzoletti M, Bortolin F, Brunelli L, et al,. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 2011; 71: 4573-84
47. Hudes G, Carducci M, Tomczak P, et al,. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81
48. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M,. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004; 15: 1510-6
49. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M,. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-5
50. Weigelt B, Warne PH, Downward J,. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222-33
51. Chen CD, Welsbie DS, Tran C, et al,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9
52. Porta C, Osanto S, Ravaud A, et al,. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-98